AZT inhibits synthesis of cancer genome by its active anabolite
AZTTP (azidothymidine triphosphate) through chain termination mechanism which may inhibit telomerase activity competitively (23).
Lamivudine undergoes anabolic phosphorylation by intracellular kinases to form lamivudine 5'-triphosphate, the active anabolite
that prevents HIV-1 and HBV replication by competitively inhibiting viral reverse transcriptase and terminating proviral DNA chain extension.
Azidothymidine is an anticancer drug that not only competitively decreases telomerase activity in tumor cells via active anabolite
azidothymidine triphosphate (AZTTP) and arrests the tumor cells by favoring apoptosis or inducing senescence (24), (25), but also through decreasing Bc1-2 expression and concentration in tumor cells lowers the resistance of the cells to apoptosis and increases their sensitivity to this drug (26).